Guillain Barre syndrome (GBS): course and prognosis

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Guillain Barre syndrome (GBS): course and prognosis. These develop following immunotherapy. Fully referenced neurology checklist.

Treatment related fluctuations (TRF): features

  • These develop following immunotherapy
  • They start within 8 weeks of treatment
  • They are probably caused by a prolonged immune response
  • They may be predicted by abnormal sweating and skin flushing
  • They may improve with repeating the treatment

Recurrences

Locked: subscribe to see this section.

Outcome

Locked: subscribe to see this section.

Poor prognostic features: clinical

Locked: subscribe to see this section.

Poor prognostic features: laboratory

Locked: subscribe to see this section.

Acronym

Locked: subscribe to see this section.

References

  1. Willison HJ, Jacobs BC, van Doorn PA. Guillain Barre syndrome. Lancet 2016 Feb 29. pii: S0140-6736(16)00339-1 (Epub ahead of print).
  2. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. JNNP 1991; 54:957-960.
  3. Demichelis C, Grisanti S, Massa F, et al. Abnormal sweating and "skin flushing" as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature. J Neurol Sci 2021; 428:117589.
  4. Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. JNNP 2002; 73:348-349.
  5. Bernsen RA, de Jager AE, van der Meche FG, Suurmeijer TP. How Guillain-Barre patients experience their functioning after 1 year. Acta Neurol Scand 2005; 112:51-56.
  6. And 18 more. Subscribe to see the full list

Related checklists

Loading...